Citius Oncology (CTOR) Stock Analysis & Winston Score

Citius Oncology is a small pharmaceutical company focused on developing and selling cancer treatments. Its lead product is LYMPHIR (denileukin diftitox), a drug approved by the FDA in 2024 to treat a rare type of skin cancer called cutaneous T-cell lymphoma. The company sells to hospitals, oncology clinics, and specialty pharmacies in the United States.

Citius Oncology earns revenue by selling LYMPHIR directly into the specialty oncology market, where it competes against other treatments for a relatively small patient population. The company is early-stage commercially, operating only in the U.S., and its high gross margin reflects typical pharmaceutical pricing power — but its deeply negative operating margin shows it is spending far more than it earns right now. The main risk is that the company must grow LYMPHIR sales fast enough to cover heavy operating costs before it runs out of cash, which is a common and serious challenge for small, single-product drug companies.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+36.8% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

94.6%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~2 months

$4M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Citius Oncology has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-9.7%

Weak — -9.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-326.8%

Burning cash (-326.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.08

Conservative — low debt load (0.08)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial